Zhi Xiang Jintai (688443.SH) received approval for the clinical trial application of the investigational product GR2301 injection.

Zhixin Finance APP News, Zhixiang Jintai (688443.SH) announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's clinical trial application for the investigational product GR2301 injection has been approved. The announcement shows that GR2301 injection is a recombinant human anti-IL-15 monoclonal antibody independently developed by the company, which can block the binding of IL-15 to IL-15R and IL-15&IL-15R complex to IL-2R&IL-2R complex, inhibit downstream JAK-STAT signaling pathway, and achieve the effect of treating autoimmune diseases such as vitiligo caused by IL-15 expression imbalance.